Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
256 pending office actions • 124 clients • 220 examiners • 94 art units • 0 of 256 (0%) have an AI response strategy ready
FOLEY HOAG, LLP (General) specializes in Biotechnology & Pharmaceuticals. The firm has handled 9062 career applications and currently manages 230 pending office actions. This reflects a significant commitment to the life sciences sector.
The firm reports a resolved allowance rate of 76.78 percent. Prosecution involves an average of 3.33 office actions per allowance. These metrics suggest a rigorous prosecution environment where the firm consistently works through multiple examiner interactions to secure patent rights.
Based on the USPTO statutory response window for each pending office action. 84 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 84 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 only | 4 (2%) |
| §101 + other | 25 (10%) |
| §103 only | 54 (21%) |
| §102 only | 11 (4%) |
| §112 only | 31 (12%) |
| Double-patenting only | 3 (1%) |
| Double-patenting + other | 38 (15%) |
| Multi-statute (no §101) | 89 (35%) |
| No statute on record | 1 (0%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| VALENROD, YEVGENY | 4 | 72.6% | +25.1% |
| RONEY, CELESTE A | 4 | 62.8% | +17.5% |
| ROZOF, TIMOTHY R | 3 | 72.7% | +23.6% |
| BYRNES, DAVID R | 3 | 78.1% | +22.2% |
| HALVORSON, MARK | 3 | 47.9% | +20.7% |
| WARD, PAUL V | 3 | 83.2% | -12.2% |
| JOHNSON, CHRISTOPHER LINDSAY | 3 | 46.9% | +81.0% |
| HERNANDEZ, JACKSON J | 3 | 51.4% | +45.0% |
| PALENIK, JEFFREY T | 2 | 53.6% | +27.2% |
| CHANG, KYUNG SOOK | 2 | 60.4% | +40.9% |
Cases in front of an examiner with an allow rate of 80%+ where the difficulty is Easy or Medium. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18532671 | TREATMENT OF AUTOIMMUNE AND INFLAMMATORY DISORDERS WITH INHIBITORS OF BET FAMILY BDII BROMODOMAIN | WARD, PAUL V | — |
| 18226621 | THERAPEUTIC USES OF UROLITHIN DERIVATIVES | WARD, PAUL V | — |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18977008 | VACCINES COMPRISING METHANOBREVIBACTER GOTTSCHALKII | FOLEY, SHANON A | 264d overdue |
| 16964965 | ANTIBODY-DRUG CONJUGATES THAT TARGET DLK1 AND USES THEREOF | PUTTLITZ, KARL J | 219d overdue |
| 18529532 | AIR CONDITIONING SYSTEM WITH MULTIPLE ENERGY STORAGE SUB-SYSTEMS | LAWRENCE JR, FRANK M | 124d overdue |
| 18014580 | INTERLEUKIN 33 (IL-33) INHIBITION FOR TREATMENT OF CANCER, FIBROSIS AND INFLAMMATION | HERNANDEZ, JACKSON J | 91d overdue |
| 18478179 | METHODS AND COMPOSITIONS FOR EDITING NUCLEOTIDE SEQUENCES | MCKNIGHT, CIARA A | 89d overdue |
| 16640942 | METHODS FOR MODULATING THE INTERACTION BETWEEN EWS-FLI1 AND BAF COMPLEXES | DENT, ALANA HARRIS | 87d overdue |
| 18283158 | VACCINE ADJUVANT | OH, TAYLOR V | 60d overdue |
| 18269869 | HEPATOCELLULAR CARCINOMA TREATMENTS, PROPHYLACTIC THERAPIES, AND COMPOSITIONS FOR USE THEREWITH | IANNUZO, NATALIE NMN | 50d overdue |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 16381791 | COMPOSITIONS AND METHODS OF IDENTIFYING TUMOR SPECIFIC NEOANTIGENS | HALVORSON, MARK | 93d overdue |
| 18014580 | INTERLEUKIN 33 (IL-33) INHIBITION FOR TREATMENT OF CANCER, FIBROSIS AND INFLAMMATION | HERNANDEZ, JACKSON J | 91d overdue |
| 18778356 | LETTUCE VARIETY 'E01G11679' | BYRNES, DAVID R | 38d overdue |
| 17917233 | MANUFACTURING OF SYNTHETIC EXOSOMES FOR CNS AND NON-CNS DELIVERY OF THERAPEUTICS | RONEY, CELESTE A | 24d overdue |
| 16094786 | IMPROVED HLA EPITOPE PREDICTION | HALVORSON, MARK | 4d overdue |
| 18007822 | METHODS OF TREATING A CORONAVIRUS INFECTION | JOHNSON, CHRISTOPHER LINDSAY | 3d overdue |
| 19074044 | FORMULATIONS FOR NEOPLASIA VACCINES | HALVORSON, MARK | 5d |
| 19170782 | ENHANCING AUTOPHAGY OR INCREASING LONGEVITY BY ADMINISTRATION OF UROLITHINS | VALENROD, YEVGENY | 55d |
| Art Unit | Apps |
|---|---|
| 1628 | 9 |
| 1625 | 8 |
| 1663 | 7 |
| 1637 | 7 |
| 1651 | 6 |
| 1662 | 6 |
| 1612 | 6 |
| 1615 | 5 |
| 1646 | 5 |
| 1626 | 5 |
| App # | Title | Client | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|---|
| 19386955 | Untitled | President and Fellows of Harvard College | GORDON, MELENIE LEE | 1651 | §103§112Other | Non-Final OA | — | Pending | |
| 19567925 | ENHANCING AUTOPHAGY OR INCREASING LONGEVITY BY ADMINISTRATION OF UROLITHINS | Amazentis SA | VALENROD, YEVGENY | 1628 | DP | Non-Final OA | — | Pending | Mar 16, 2026 |
| 19542047 | COMPOSITIONS AND METHODS FOR TREATING PULMONARY ARTERIAL HYPERTENSION | Inhibikase Therapeutics, Inc. | ROZOF, TIMOTHY R | 1625 | §102§103 | Final Rejection | — | Pending | Feb 17, 2026 |
| 19436348 | COMPOSITIONS COMPRISING AN ACTIVE INGREDIENT MIXTURE COMPRISING SILICON AND BIOTIN AND METHODS OF USE | Nutrition21, LLC | PALENIK, JEFFREY T | 1615 | §102§103DP | Final Rejection | — | Pending | Dec 30, 2025 |
| 19371866 | FORMULATIONS COMPRISING INOSITOL, SILICATES, AND OPTIONALLY AMINO ACIDS WITH IMPROVED SOLUBILITY AND METHODS OF MAKING THE SAME | Nutrition21, LLC | TCHERKASSKAYA, OLGA V | 1615 | §103§112DP | Final Rejection | — | Pending | Oct 28, 2025 |
| 19311619 | ENHANCING AUTOPHAGY OR INCREASING LONGEVITY BY ADMINISTRATION OF UROLITHINS | Amazentis SA | VALENROD, YEVGENY | 1628 | §103 | Non-Final OA | — | Pending | Aug 27, 2025 |
| 19304291 | HYBRID TOMATO VARIETIES 'E15C42784', 'E15C42790', AND 'E15C42808' | Enza Zaden Beheer B.V. | LOGSDON, CHARLES | §112Other | Non-Final OA | — | Pending | Aug 19, 2025 | |
| 19179503 | HYBRID PEPPERS 'E20B.30395' AND 'E20B.30396' | Enza Zaden Beheer B.V. | BYRNES, DAVID R | 1662 | §101§112 | Non-Final OA | — | Pending | Apr 15, 2025 |
| 19170782 | ENHANCING AUTOPHAGY OR INCREASING LONGEVITY BY ADMINISTRATION OF UROLITHINS | Amazentis SA | VALENROD, YEVGENY | 1628 | §103 | Non-Final OA | 55d | Pending | Apr 04, 2025 |
| 19095805 | HIDDEN DESKTOP SESSION FOR REMOTE ACCESS | Connectwise, LLC | TANG, KAREN C | §103Other | Non-Final OA | — | Pending | Mar 31, 2025 | |
| 19116095 | METHOD FOR SELECTING AN S. LYCOPERSICUM PLANT TOLERANT TO HIGH TEMPERATURE CONDITIONS | Enza Zaden Beheer B.V. | STANKOVIC, BRATISLAV | 1662 | §101§102§103§112 | Non-Final OA | — | Pending | Mar 27, 2025 |
| 19080090 | RETRACTABLE MOLD BUILT-IN PRECISION PINS TO LOCATE COMPONENTS DURING LAYUP PROCESS FOR FABRICATION OF WIND TURBINE BLADES | Tpi Technology Inc. | DANIELS, MATTHEW J | §103§112 | Non-Final OA | — | Pending | Mar 14, 2025 | |
| 19074044 | FORMULATIONS FOR NEOPLASIA VACCINES | The Broad Institute, Inc. | HALVORSON, MARK | 1646 | §112 | Final Rejection | 5d | Pending | Mar 07, 2025 |
| 19067282 | DELIVERY OF SUSTAINED LOCAL AND SYSTEMIC IMMUNOMODULATION | The Brigham And Women'S Hospital, Inc. | CHANG, KYUNG SOOK | §103§112 | Non-Final OA | — | Pending | Feb 28, 2025 | |
| 19052818 | LETTUCE VARIETIES ‘EZTREME’ AND ‘NIGHTHAWK’ | Enza Zaden Beheer B.V. | ZHONG, WAYNESHAOBIN | §112 | Non-Final OA | — | Pending | Feb 13, 2025 | |
| 19008130 | SPEAKER WITH OBLIQUE MOUNTED BASS DRIVER | Lenbrook Industries Limited | GAUTHIER, GERALD | §102 | Non-Final OA | — | Pending | Jan 02, 2025 | |
| 18877765 | COMPOSITIONS AND METHODS FOR TREATING HEARING AND OCULAR DISORDERS | Anida Pharma Inc. | JARRELL, NOBLE E | 1629 | §102§103 | Non-Final OA | — | Pending | Dec 20, 2024 |
| 18978865 | HYBRID TOMATO VARIETIES ‘E15M43062’ AND ‘E16R43164’ | Enza Zaden Beheer B.V. | BOGGS, RUSSELL T | 1663 | §112 | Non-Final OA | — | Pending | Dec 12, 2024 |
| 18977008 | VACCINES COMPRISING METHANOBREVIBACTER GOTTSCHALKII | Arkea Bio Corp. | FOLEY, SHANON A | 1671 | §103§112 | Non-Final OA | 264d overdue | Pending | Dec 11, 2024 |
| 18873070 | NOVEL TREATMENT | University Of Liverpool | HASTINGS, ALISON AZAR | §103§112 | Non-Final OA | — | Pending | Dec 09, 2024 | |
| 18869024 | LETTUCE PLANT RESISTANT TO DOWNY MILDEW AND RESISTANCE GENE | Enza Zaden Beheer B.V. | WILLIAMS, KEITH RICHARD | 1663 | §103§112 | Final Rejection | — | Pending | Nov 25, 2024 |
| 18867152 | LIPIDS FOR DELIVERY OF THERAPEUTIC AGENTS | Sepia Therapeutics, Inc. | STEVENS, MARK V | 1613 | §112 | Non-Final OA | — | Pending | Nov 19, 2024 |
| 18947339 | SYSTEM AND METHOD TO RADIALLY CONSTRICT A STENT GRAFT | Bolton Medical, Inc. | RWEGO, KANKINDI | 3771 | §102§103Other | Final Rejection | — | Pending | Nov 14, 2024 |
| 18863566 | IMMUNOBIOTICS FOR PREVENTING BACTERIAL PNEUMONIA AND METHODS OF USING THE SAME | The Regents of the University of Colorado | OGUNBIYI, OLUWATOSIN A | §102§103§112 | Non-Final OA | — | Pending | Nov 06, 2024 | |
| 18861976 | CHEST BOLT AND THORACOSTOMY BOLT | Spinthyr Technologies, LLC | LONG, SARAH A | 3771 | §102§103§112 | Final Rejection | 28d overdue | Pending | Oct 31, 2024 |
| 18927310 | ANIMAL POSITIONING AND MONITORING SYSTEM FOR MICROSCOPY | Northeastern University | MORALES, JON ERIC C | 3786 | §102 | Non-Final OA | — | Pending | Oct 25, 2024 |
| 18913578 | ARCHITECTURES OF LARGE LANGUAGE MODELS FOR MEDICAL TREATMENT DECISION SUPPORT | Trialmatch.Me, Inc. D/B/A/Trialjectory | ZHU, RICHARD Z | 2654 | §103 | Non-Final OA | — | Pending | Oct 11, 2024 |
| 18913731 | DNA COLLECTION DEVICE | Sapphiros Laboratories LLC | MELHUS, BENJAMIN S | §102§112 | Non-Final OA | — | Pending | Oct 11, 2024 | |
| 18912145 | TEST PLUG FOR SPRINKLER ADAPTER | Ipex Usa LLC | LU, HAOTIAN | §103 | Non-Final OA | — | Pending | Oct 10, 2024 | |
| 18907230 | FEATURE PYRAMIDING FOR IN SITU DATA VISUALIZATIONS (AKA DYNAMIC DISPLAY OF MOLECULAR INFORMATION DEPENDENT ON ZOOM LEVEL) | 10X Genomics, Inc. | HUYNH, VAN D | §102§103 | Non-Final OA | — | Pending | Oct 04, 2024 | |
| 18897839 | STYLUS DERIVED METRICS TO DETECT CENTRAL AND PERIPHERAL NERVOUS SYSTEM ATTRIBUTES | Linus Health, Inc. | OGLES, MATTHEW ERIC | 3792 | §101§102§103§112 | Non-Final OA | — | Pending | Sep 26, 2024 |
| 18894797 | HUMAN PLASMA KALLIKREIN INHIBITORS | Biocryst Pharmaceuticals, Inc. | SAEED, KAMAL A | DP | Non-Final OA | — | Pending | Sep 24, 2024 | |
| 18891617 | CRYSTALLINE SALT FORMS OF BOC-D-ARG-DMT-LYS-(BOC)-PHE-NH2 | Stealth BioTherapeutics Inc. | REYNOLDS, FRED H | §112DP | Non-Final OA | — | Pending | Sep 20, 2024 | |
| 18886316 | GENOTYPE-AGNOSTIC RESCUE OF CYSTIC FIBROSIS WITH SMALL MOLECULE BICARBONATE CHANNELS | UNIVERSITY OF IOWA RESEARCH FOUNDATION | RONEY, CELESTE A | §103DP | Non-Final OA | — | Pending | Sep 16, 2024 | |
| 18886318 | GENOTYPE-AGNOSTIC RESCUE OF CYSTIC FIBROSIS WITH SMALL MOLECULE BICARBONATE CHANNELS | UNIVERSITY OF IOWA RESEARCH FOUNDATION | RONEY, CELESTE A | §103§112DP | Non-Final OA | — | Pending | Sep 16, 2024 | |
| 18885581 | Inter-Frequency Signal Aiding For Tracking Satellite Navigation Signals | The Regents of the University of Colorado | GREGORY, BERNARR E | 3648 | §101§103§112 | Non-Final OA | — | Pending | Sep 14, 2024 |
| 18845749 | LIPID NANOPARTICLES FOR TARGETED DELIVERY OF MRNA | Trustees Of Tufts College | SONG, JIANFENG | 1613 | §102DP | Non-Final OA | — | Pending | Sep 10, 2024 |
| 18828513 | PERIODIC EXTENSIONAL FLOW REACTOR | United States Army Research Laboratory | MORENO HERNANDEZ, JERZI H | 1743 | §102§103§112 | Non-Final OA | — | Pending | Sep 09, 2024 |
| 18845283 | METHODS OF TREATING CANCER AND OTHER CONDITIONS WITH A MU OPIOID RECEPTOR ANTAGONIST | Glycyx Mor Inc. | LEE, CHIHYI NMN | §102§103§112DP | Non-Final OA | — | Pending | Sep 09, 2024 | |
| 18827231 | METHODS OF TREATING COGNITIVE IMPAIRMENT | Neurotherapia, Inc. | SANCHEZ, JUSTIN CHRISTOPHER | §103§112 | Non-Final OA | — | Pending | Sep 06, 2024 | |
| 18842526 | SPINACH PLANT RESISTANT TO DOWNY MILDEW AND NOVEL RESISTANCE GENE | Enza Zaden Beheer B.V. | ORDAZ, CHRISTIAN JOSE | 1663 | §112 | Final Rejection | 26d | Pending | Aug 29, 2024 |
| 18819461 | COMPUTATIONAL SIMULATION PLATFORM FOR PLANNING OF INTERVENTIONAL PROCEDURES | The Board Of Regents Of The University Of Nebraska | TORRES, JOSE | §103§112 | Non-Final OA | — | Pending | Aug 29, 2024 | |
| 18841884 | COMPOSITIONS COMPRISING AN ACTIVE INGREDIENT MIXTURE COMPRISING SILICON AND BIOTIN AND METHODS OF USE | Nutrition21, LLC | PALENIK, JEFFREY T | §102 | Non-Final OA | — | Pending | Aug 27, 2024 | |
| 18812309 | THERAPEUTIC ALKALOID COMPOUNDS | Sensorium Therapeutics, Inc. | ROZOF, TIMOTHY R | §102DP | Non-Final OA | — | Pending | Aug 22, 2024 | |
| 18806984 | DELIVERY OF THERAPEUTIC ALKALOID COMPOUNDS | Sensorium Therapeutics, Inc. | RZECZYCKI, PHILLIP MATTHEW | §103§112DP | Non-Final OA | — | Pending | Aug 16, 2024 | |
| 18799074 | ALKYL-SUBSTITUTED DERIVATIVES OF MESEMBRINE AND MESEMBRENONE AND THERAPEUTIC USES THEREOF | Sensorium Therapeutics, Inc. | BRAUN, MADELINE E | §103DP | Non-Final OA | — | Pending | Aug 09, 2024 | |
| 18799146 | DELIVERY OF THERAPEUTIC ALKALOID COMPOUNDS | Sensorium Therapeutics, Inc. | SAEED, KAMAL A | DP | Non-Final OA | — | Pending | Aug 09, 2024 | |
| 18799037 | THERAPEUTIC ALKALOID COMPOUNDS | Sensorium Therapeutics, Inc. | HABTE, KAHSAY | §112 | Non-Final OA | — | Pending | Aug 09, 2024 | |
| 18799720 | METHOD FOR PRODUCING A COATED PERFORATED STEEL STRIP | Voestalpine Stahl GmbH | PENNY, TABATHA L | 1712 | §103 | Final Rejection | — | Pending | Aug 09, 2024 |
| 18790836 | EXTENSIBILITY NETWORKING LAYER OF AN INTEGRATION SYSTEM | Connectwise, LLC | NGUYEN, HAO HONG | 2447 | §103 | Final Rejection | 70d | Pending | Jul 31, 2024 |
| 18784462 | DEVICES FOR IMPLANTATION OF CELLULAR TRANSPLANTS AND METHODS OF USING THE SAME | The Regents of the University of Colorado | MULLINS, JESSICA LYNN | 3792 | §102§103§112 | Non-Final OA | — | Pending | Jul 25, 2024 |
| 18783046 | LETTUCE VARIETY 'SUNBERG’ | Enza Zaden Beheer B.V. | ZHONG, WAYNESHAOBIN | 1662 | §112 | Non-Final OA | 65d | Pending | Jul 24, 2024 |
| 18778356 | LETTUCE VARIETY 'E01G11679' | Enza Zaden Beheer B.V. | BYRNES, DAVID R | 1662 | §112 | Final Rejection | 38d overdue | Pending | Jul 19, 2024 |
| 18768496 | TREATMENT OF MIGRAINE | Allergan Pharmaceuticals International Limited | ROZOF, TIMOTHY R | §103DP | Non-Final OA | — | Pending | Jul 10, 2024 | |
| 18725593 | BICYCLIC INHIBITORS OF NICOTINAMIDE NMETHYLTRANSFERASE, COMPOSITIONS AND USES THEREOF | President and Fellows of Harvard College | HEITMEIER, KENDALL NICOLE | §102§112 | Non-Final OA | — | Pending | Jun 28, 2024 | |
| 18724189 | ACIDIC SALT OR CRYSTAL FORM OF NITROGEN-CONTAINING FUSED RING DERIVATIVE INHIBITOR, AND PREPARATION METHOD THEREFOR AND USE THEREOF | Changzhou Hansoh Pharmaceutical Co., Ltd. | BRAUN, MADELINE E | §103§112DP | Non-Final OA | — | Pending | Jun 25, 2024 | |
| 18722389 | LETTUCE PLANT RESISTANT TO DOWNY MILDEW AND RESISTANCE GENE | Enzazaden Beheer B.V. | ORDAZ, CHRISTIAN JOSE | 1663 | §112 | Final Rejection | — | Pending | Jun 20, 2024 |
| 18746393 | BIOACTIVE PEPTIDES AND METHODS OF USE THEREOF | Op-T LLC | CHESTNUT, BARRY A | §103DP | Non-Final OA | — | Pending | Jun 18, 2024 | |
| 18744204 | OBFUSCATING ANALOG CIRCUITS USING SWITCHED PHASE CIRCUITS | Northeastern University | ANDERSON, MICHAEL D | 2433 | §103 | Final Rejection | — | Pending | Jun 14, 2024 |
| 18741322 | COMPOSITIONS AND METHODS FOR TREATING CANCER | The Regents of the University of California | CHICKS, ASHLI ARIANA | Other | Non-Final OA | — | Pending | Jun 12, 2024 | |
| 18741036 | CELLULAR USER LOCALIZATION SYSTEM: SMS SIDE-CHANNEL TIMING ANALYSIS METHOD AND APPARATUS | Technical University Of Dortmund | RIVAS, RAUL | 4100 | §101§103 | Non-Final OA | — | Pending | Jun 12, 2024 |
| 18736997 | BCMA CHIMERIC ANTIGEN RECEPTORS | 2Seventy Bio, Inc. | ARON, KIMBERLY A | §103DP | Non-Final OA | — | Pending | Jun 07, 2024 | |
| 18734482 | LOW AFFINITY FcyR DEFICIENT MICE | Regeneron Pharmaceuticals, Inc. | WILSON, MICHAEL C | 1638 | §112Other | Non-Final OA | — | Pending | Jun 05, 2024 |
| 18714670 | DIAGNOSTIC TEST | Apis Assay Technologies Ltd. | KENNEDY, SARAH JANE | §101§102 | Non-Final OA | — | Pending | May 30, 2024 | |
| 18713947 | COMPOSITIONS AND METHODS FOR INHIBITING SEIZURES | The Regents of the University of California | CURRENS, GRANT CARSON | 1651 | §101§102§103§112 | Non-Final OA | — | Pending | May 28, 2024 |
| 18712285 | INDOLINES AS PROTAC COMPOUNDS | Neophore Limited | SHI, GENBIN | §103§112 | Non-Final OA | — | Pending | May 22, 2024 | |
| 18712311 | ISOINDOLINES AS PMS2 INHIBITORS | Neophore Limited | NOLAN, JASON MICHAEL | §112 | Non-Final OA | — | Pending | May 22, 2024 | |
| 18669928 | SYNTHETIC FUELS, AND METHODS AND APPARATUS FOR PRODUCTION THEREOF | Air Company Holdings, Inc. | PO, MING CHEUNG | 1771 | §103 | Final Rejection | — | Pending | May 21, 2024 |
| 18670099 | PERISTALTIC PUMPING OF FLUIDS AND ASSOCIATED METHODS, SYSTEMS, AND DEVICES | Quantum-Si Incorporated | KASTURE, DNYANESH G | 3746 | §102§103§112 | Non-Final OA | 15d overdue | Pending | May 21, 2024 |
| 18711184 | SOLID FORMS OF MESEMBRINE AND THERAPEUTIC USES THEREOF | Sensorium Therapeutics, Inc. | KUCHARCZK, JED A | §102 | Non-Final OA | — | Pending | May 17, 2024 | |
| 18654512 | LETTUCE VARIETIES ‘E01C11866’, ‘E01L30616’ AND ‘E01B11959’ | Enza Zaden Beheer B.V. | DEVEAU ROSEN, JASON | 1662 | §112 | Non-Final OA | — | Pending | May 03, 2024 |
| 18650592 | BIOLOGICALLY SELECTED NUCLEIC ACID ARTIFICIAL MINI-PROTEOME LIBRARIES | DANA-FARBER CANCER INSTITUTE, INC. | OLSON, ALEXANDRA NADINE | §103§112DP | Non-Final OA | — | Pending | Apr 30, 2024 | |
| 18649438 | USE OF ACIDIC ELECTROLYTE CATIONS FOR SELECTIVE ELECTROCHEMICAL CO2 AND CO CONVERSIONS TO METHANOL | Massachusetts Institute Of Technology | WONG, EDNA | 1795 | §103§112 | Non-Final OA | — | Pending | Apr 29, 2024 |
| 18705706 | DEUTERATED FORMS OF ALKALOID COMPOUNDS AND THERAPEUTIC USES THEREOF | Sensorium Therapeutics, Inc. | AULAKH, CHARANJIT | 1621 | §102§112 | Final Rejection | — | Pending | Apr 29, 2024 |
| 18647916 | PREDICTIVE RFM SEGMENTATION | Punchh Inc. | EL-HAGE HASSAN, ABDALLAH A | 3623 | §101 | Non-Final OA | 5d | Pending | Apr 26, 2024 |
| 18647310 | IMIDAZOLE-CONTAINING INHIBITORS OF ALK2 KINASE | Biocryst Pharmaceuticals, Inc. | CORNET, JEAN P | §103§112DP | Non-Final OA | — | Pending | Apr 26, 2024 | |
| 18639592 | COMPOSITIONS AND METHODS FOR MODULATING HYDROXYLATION OF ACC2 BY PHD3 | President and Fellows of Harvard College | NATARAJAN, MEERA | §112 | Non-Final OA | — | Pending | Apr 18, 2024 | |
| 18702703 | GENOME EDITING COMPOSITIONS AND METHODS FOR TREATMENT OF USHER SYNDROME TYPE 3 | Prime Medicine, Inc. | VIJAYARAGHAVAN, JAGAMYA NMN | 1633 | §103§112 | Non-Final OA | — | Pending | Apr 18, 2024 |
| 18635442 | PERICELLULAR OXYGEN-CONTROLLING CELL CULTURE INCUBATOR | Northeastern University | HAQ, SHAFIQUL | §103 | Non-Final OA | — | Pending | Apr 15, 2024 | |
| 18634105 | MODULAR, REPLACEABLE OUTBOARD FAIRINGS FOR APPLICATION SPECIFIC OPTIMIZATION | Flux Marine Ltd. | VASUDEVA, AJAY | 3615 | §103§112 | Final Rejection | — | Pending | Apr 12, 2024 |
| 18700487 | COMPOSITIONS AND METHODS FOR TREATING ALPHA-1 ANTITRYPSIN DEFICIENCY | Intellia Therapeutics, Inc. | TATGE, LEXUS MARC | §101§103§112DP | Non-Final OA | — | Pending | Apr 11, 2024 | |
| 18627964 | SYSTEMS AND METHODS FOR MOBILE SPEECH HEARING OPTIMIZATION | Linus Health, Inc. | ROBERTS, ANNA L | 3791 | §101§102§103§112 | Non-Final OA | 4d overdue | Pending | Apr 05, 2024 |
| 18627309 | CELLULAR TRANSPLANT CARRIER DEVICES AND METHODS OF USING THE SAME | The Regents of the University of Colorado | GRAY, PHILLIP A | §102§103§112 | Non-Final OA | — | Pending | Apr 04, 2024 | |
| 18697411 | DIAGNOSING MULTIPLE SCLEROSIS (MS) | The Regents of the University of Colorado | COLE, HOUSTON DAVID | §101§102§103§112 | Non-Final OA | — | Pending | Mar 29, 2024 | |
| 18608256 | MODULAR SEMI-SUBMERSIBLE OFFSHORE PLATFORM | Aikido Technologies, Inc. | VENNE, DANIEL V | 3615 | §101§102§103§112Other | Non-Final OA | — | Pending | Mar 18, 2024 |
| 18608002 | METHODS FOR ESTIMATING AND SERVING WAKE WINDOW PREDICTIONS BASED ON SLEEP DATA | Huckleberry Labs, Inc. | WILLOUGHBY, ALICIA M | §101§103§112 | Non-Final OA | — | Pending | Mar 18, 2024 | |
| 18606313 | METHODS AND CATALYSTS FOR CARBON DIOXIDE CONVERSION TO LONG-CHAIN HYDROCARBONS | Air Company Holdings, Inc. | JEONG, YOUNGSUL | 1772 | §103 | Final Rejection | 33d | Pending | Mar 15, 2024 |
| 18690382 | SUBSTRATES AND BIOMARKERS OF ADAMTS7 | The Broad Institute, Inc. | PAGUIO FRISING, MICHELLE F | 1651 | §112 | Non-Final OA | — | Pending | Mar 08, 2024 |
| 18596170 | TECHNIQUES FOR REAL-TIME RESPONSE STRATEGIES IN A SUPPLY CHAIN | Cognosos, Inc. | EL-BATHY, IBRAHIM N | 3628 | §101 | Non-Final OA | 31d overdue | Pending | Mar 05, 2024 |
| 18687436 | METHODS FOR THE GENERATION OF HUMAN RETINAL GANGLION CELLS AND COMPOSITIONS, ASSAYS, DEVICES, AND KITS COMPRISING SAME | Albert Einstein College of Medicine | BARRON, SEAN C | 1653 | §103§112 | Non-Final OA | — | Pending | Feb 28, 2024 |
| 18687601 | COMPOSITION COMPRISING a-KETOGLUTARIC ACID (a-KG) AND 5-HYDROXYMETHYL-2-FURFURAL (5-HMF) TO IMPROVE HEMOGLOBIN-MEDIATED OXYGEN SUPPLY | Cyl GmbH | CLARK, AMY LYNN | 1628 | §102§103§112 | Non-Final OA | — | Pending | Feb 28, 2024 |
| 18687108 | TREATING LONG COVID-19 WITH UROLITHINS | Amazentis SA | CORNET, JEAN P | 1628 | §103§112 | Non-Final OA | — | Pending | Feb 27, 2024 |
| 18684986 | AMPHIPHILIC POLYAMPHOLYTES AND RELATED MEMBRANES | Trustees Of Tufts College | LEE, RIP A | §102§112 | Non-Final OA | — | Pending | Feb 20, 2024 | |
| 18444288 | PROTEIN SOLUTION FORMULATION CONTAINING HIGH CONCENTRATION OF AN ANTI-VEGF ANTIBODY | Novartis AG | KIM, YUNSOO | §102§103DP | Non-Final OA | — | Pending | Feb 16, 2024 | |
| 18683663 | RADIOFLUORINATED AGENTS FOR PET IMAGING SELECTIVELY TARGETING FIBROBLAST ACTIVATION PROTEIN | Trustees Of Tufts College | LIPPERT, JOHN WILLIAM | §103 | Non-Final OA | — | Pending | Feb 14, 2024 | |
| 18440188 | CLEAVABLE LINKER-CONTAINING IONIZABLE LIPIDS AND LIPID CARRIERS FOR THERAPEUTIC COMPOSITIONS | Flagship Pioneering Innovations Vii, LLC | HOLLOMAN, NANNETTE | 1612 | §102§103 | Non-Final OA | — | Pending | Feb 13, 2024 |
| 18682544 | WOUND MONITORING SYSTEM AND SENSOR THEREOF | National University Of Singapore | WESTFALL, SARAH ANN | 3791 | §102§103§112 | Non-Final OA | 26d | Pending | Feb 09, 2024 |
| 18437633 | NON-PROTEIN CLOSTRIDIAL TOXIN COMPOSITIONS | Allergan, Inc. | BERKE-SCHLESSEL, DAVID W | 1651 | §103§112Other | Non-Final OA | — | Pending | Feb 09, 2024 |
| 18431278 | DUAL CAP SYSTEM FOR CONTAINER-CLOSURES TO MAINTAIN TIP STERILITY DURING SHELF STORAGE | Allergan, Inc. | DAVISON, LAURA L | 3993 | §103Other | Non-Final OA | 22d | Pending | Feb 02, 2024 |
| 18431448 | PARAMETRIC AND AUTOMATED TOOL FOR THE DESIGN OF STEEL SUBSTRUCTURE OF COMPOSITE MOLDS | Tpi Technology, Inc. | ARTHUR JEANGLAUDE, GERTRUDE | 3661 | §102§103 | Non-Final OA | 9d | Pending | Feb 02, 2024 |
| 18427141 | RESISTANCE GENE AND LETTUCE PLANT RESISTANT TO DOWNY MILDEW | Enza Zaden Beheer B.V. | BYRNES, DAVID R | 1662 | §112DP | Non-Final OA | — | Pending | Jan 30, 2024 |
| 18421666 | EX-VIVO CULTURE SYSTEM AND METHODS OF USING SAME | Yeda Research And Development Co. Ltd. | ZHANG SPIERING, DONGXIU | 1616 | §103 | Non-Final OA | — | Pending | Jan 24, 2024 |
| 18420205 | AORTIC PROSTHESIS WITH TUNNEL GRAFT AND EMBOLIC FILTER | Bolton Medical, Inc. | HOUSTON, ELIZABETH | 3771 | §103§112 | Non-Final OA | — | Pending | Jan 23, 2024 |
| 18413789 | BLOCKCHAIN-BASED PLATFORM FOR HEALTH RECORD EXCHANGE | Blue Cross And Blue Shield Of Massachusetts, Inc. | EDOUARD, JONATHAN CHRISTOPHER | 3683 | §101§103 | Non-Final OA | — | Pending | Jan 16, 2024 |
| 18576696 | COMPOSITIONS AND METHODS FOR DECREASING PIGMENTATION | The General Hospital Corporation | GREENE, IVAN A | 1619 | §102§103 | Non-Final OA | — | Pending | Jan 04, 2024 |
| 18574587 | SEAWATER ELECTROLYSIS ENABLES SCALABLE ATMOSPHERIC CO2 MINERALIZATION | The Regents of the University of California | PARENT, ALEXANDER RENE | §103§112Other | Non-Final OA | — | Pending | Dec 27, 2023 | |
| 18532632 | TREATMENT OF MYELOPROLIFERATIVE DISEASES AND DISORDERS WITH INHIBITORS OF BET FAMILY BDII BROMODOMAIN | The Regents of the University of California | ANDERSON, REBECCA L | 1626 | §102§103§112Other | Non-Final OA | — | Pending | Dec 07, 2023 |
| 18532671 | TREATMENT OF AUTOIMMUNE AND INFLAMMATORY DISORDERS WITH INHIBITORS OF BET FAMILY BDII BROMODOMAIN | The Regents of the University of California | WARD, PAUL V | 1622 | §112 | Non-Final OA | — | Pending | Dec 07, 2023 |
| 18529532 | AIR CONDITIONING SYSTEM WITH MULTIPLE ENERGY STORAGE SUB-SYSTEMS | Transaera, Inc. | LAWRENCE JR, FRANK M | 1776 | §102§103 | Non-Final OA | 124d overdue | Pending | Dec 05, 2023 |
| 18526900 | NUCLEAR TRANSPORT MODULATORS AND USES THEREOF | Karyopharm Therapeutics Inc. | RODRIGUEZ-GARCIA, VALERIE | 1621 | §103Other | Non-Final OA | — | Pending | Dec 01, 2023 |
| 18526510 | CAPPED SYRINGES AND METHODS OF SEALING SAME | Discgenics, Inc. | FAROOQ, MAHMOOD | 3783 | §102§103 | Non-Final OA | — | Pending | Dec 01, 2023 |
| 18566270 | COMPOSITIONS AND METHODS FOR TREATING CELIAC DISEASE | The Regents of the University of California | ISMAIL, REHANA | 1625 | §102§103§112 | Non-Final OA | — | Pending | Dec 01, 2023 |
| 18563294 | METHOD FOR MONITORING PANCREATIC BETA-CELL DESTRUCTION IN DISEASE PREDICTION/DIAGNOSIS/PROGNOSIS OF TYPE 2 DIABETES MELLITUS | Ekaterini Chatzaki | GEDRA, OLIVIA ROSE | 3681 | §101§103 | Non-Final OA | — | Pending | Nov 21, 2023 |
| 18562719 | MPLA COMPOSITIONS AND METHODS OF USE | Revelation Biosciences, Inc. | TIEN, LUCY MINYU | 1612 | §103DP | Final Rejection | 17d overdue | Pending | Nov 20, 2023 |
| 18561805 | ROBUST, HIGH-THERMAL CONDUCTANCE, CAPILLARITY-ENABLED THIN-FILM DRY CONDENSING SURFACES | Massachusetts Institute Of Technology | NOUKETCHA, LIONEL W | 3700 | §103 | Final Rejection | — | Pending | Nov 17, 2023 |
| 18511368 | CO-DEACIDIFICATION AND DECHLORINATION OF AQUEOUS/GASEOUS STREAMS BY MINERAL DISSOLUTION | The Regents of the University of California | MENDOZA, WILSON GALLARDO | 1772 | §103§112 | Final Rejection | 40d | Pending | Nov 16, 2023 |
| 18511413 | CHROMIUM CONTAINING COMPOSITIONS FOR IMPROVING HEALTH AND FITNESS | Nutrition21, LLC | CHEN, CATHERYNE | 1655 | §101§102 | Final Rejection | 19d overdue | Pending | Nov 16, 2023 |
| 18507648 | SYSTEMS AND METHODS FOR HEAT EXCHANGE | 10X Genomics, Inc. | ABEL, LENORA A | 1799 | §103§112 | Non-Final OA | — | Pending | Nov 13, 2023 |
| 18507360 | SYSTEMS AND METHODS FOR THERMAL MANAGEMENT OF REAGENT WELL PLATES | 10X Genomics, Inc. | MOORE, DEVON TYLEN | 3763 | §103 | Non-Final OA | — | Pending | Nov 13, 2023 |
| 18289836 | Targeting Extracellular Matrix Proteins to Regulate NK Cell Function in Peripheral Tissues | The General Hospital Corporation | PRIEST, JESSICA MARIE | 1642 | §102§112Other | Non-Final OA | — | Pending | Nov 07, 2023 |
| 18503569 | AORTIC PROSTHESIS DELIVERY DEVICE AND METHOD OF USE | Bolton Medical, Inc. | BARIA, DINAH N | 3774 | §102§112 | Final Rejection | 34d | Pending | Nov 07, 2023 |
| 18289418 | MIRNA INHIBITORS FOR PREVENTING AND TREATING ANEURYSMS, HYPERTENSION, ARDS AND OTHER DISEASES ASSOCIATED WITH ENDOTHELIAL DYSFUNCTION | The Regents of the University of California | GIBBS, TERRA C | 1635 | §103§112 | Non-Final OA | — | Pending | Nov 03, 2023 |
| 18499663 | METHODS AND DEVICES OF GENERATING CLUSTERS OF AMPLICONS | Esbiolab LLC | BUNKER, AMY M | §102§103§112 | Non-Final OA | — | Pending | Nov 01, 2023 | |
| 18556563 | TISSUE-SPECIFIC NUCLEIC ACID DELIVERY BY MIXED CATIONIC LIPID PARTICLES | Sepia Therapeutics, Inc. | GULLEDGE, BRIAN M | 1637 | §103 | Non-Final OA | — | Pending | Oct 20, 2023 |
| 18287784 | METHODS OF PREPARING AN EXTRACORPOREAL CIRCUIT FOR ANTICOAGULATION | Lawell Therapeutics, LLC | DEAK, LESLIE R | 3799 | §102 | Final Rejection | 3d overdue | Pending | Oct 20, 2023 |
| 18287229 | LIPID NANOPARTICLES COMPOSITIONS | Intellia Therapeutics, Inc. | JOHNSON, CHRISTOPHER LINDSAY | 1691 | §102§103DP | Non-Final OA | — | Pending | Oct 17, 2023 |
| 18287227 | INHIBITORS OF DNA-DEPENDENT PROTEIN KINASE AND COMPOSITIONS AND USES THEREOF | Intellia Therapeutics, Inc. | HEASLEY, MEGHAN CHRISTINE | 1626 | §103 | Non-Final OA | — | Pending | Oct 17, 2023 |
| 18286037 | 1,3,4-OXADIAZOLE THIOCARBONYL COMPOUNDS AS HISTONE DEACETYLASE 6 INHIBITOR, AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | Chong Kun Dang Pharmaceutical Corp. | ENGLISH, CONNOR KENNEDY | 1625 | §112 | Non-Final OA | — | Pending | Oct 06, 2023 |
| 18285621 | METHODS FOR CONTROLLING IMMUNE CELL ACTIVITY | BIOSCEPTRE (AUST) PTY LTD | SZPERKA, MICHAEL EDWARD | 1641 | §102§112 | Non-Final OA | — | Pending | Oct 04, 2023 |
| 18285570 | SILICA-BASED FORMULATIONS OF THERAPEUTIC OLIOGPEPTIDES AND PEPTIDOMIMETICS | Stealth BioTherapeutics Inc. | TIEN, LUCY MINYU | 1612 | §103DP | Final Rejection | 7d | Pending | Oct 04, 2023 |
| 18374983 | HYBRID PEPPER VARIETY 'E20S0465' | Enza Zaden Beheer B.V. | FAN, WEIHUA | 1663 | §112 | Non-Final OA | — | Pending | Sep 29, 2023 |
| 18478179 | METHODS AND COMPOSITIONS FOR EDITING NUCLEOTIDE SEQUENCES | Prime Medicine, Inc. | MCKNIGHT, CIARA A | 1656 | §103§112 | Final Rejection | 89d overdue | Pending | Sep 29, 2023 |
| 18473740 | ORAL CARE COMPOSITIONS COMPRISING GERANYLGERANIOL AND METHODS OF USE THEREOF | American River Nutrition, LLC | GEMBEH, SHIRLEY V | 1615 | §102§103 | Non-Final OA | — | Pending | Sep 25, 2023 |
| 18283391 | BORONIC ACID COMPOUNDS, COMPOSITIONS AND METHODS | Trustees Of Tufts College | DONOHUE, SEAN R | 1618 | §103§112DP | Final Rejection | — | Pending | Sep 21, 2023 |
| 18283158 | VACCINE ADJUVANT | Celleron Therapeutics Limited | OH, TAYLOR V | 1625 | §103§112 | Final Rejection | 60d overdue | Pending | Sep 20, 2023 |
| 18282671 | CLINICAL DECISION SUPPORT SYSTEMS EMPLOYING REVERSE PHENOTYPING | Albert Einstein College of Medicine | EVANS, TRISTAN ISAAC | 3683 | §101§103 | Final Rejection | 1d overdue | Pending | Sep 18, 2023 |
| 18281045 | NOVEL CELL THERAPY SYSTEM | Biosceptre ( Aust ) Pty Ltd. | JOHANSEN, PETER N. | 1644 | §103§112 | Non-Final OA | — | Pending | Sep 08, 2023 |
| 18280593 | SMART MECHANICAL METAMATERIALS WITH TUNABLE STIMULI-RESPONSIVE EXPANSION COEFFICIENTS | Northeastern University | EWALD, MARIA VERONICA | 1783 | §103§112 | Final Rejection | 35d overdue | Pending | Sep 06, 2023 |
| 18455380 | PROGRAMMABLE RNA WRITING USING CRISPR EFFECTORS AND TRANS-SPLICING TEMPLATES | Massachusetts Institute Of Technology | WARD, AARON DUREL | 1636 | §102§103 | Non-Final OA | — | Pending | Aug 24, 2023 |
| 18234690 | RNA-TRIGGERED PROTEIN CLEAVAGE AND APPLICATIONS BY THE CRISPR CAS7-11-CSX29 COMPLEX | The University of Tokyo | ZARA, JANE J | 1637 | §112 | Final Rejection | 9d overdue | Pending | Aug 16, 2023 |
| 18277522 | COMPOSITIONS AND METHODS FOR TREATING TAUOPATHIES | The Regents of the University of California | WARD, PAUL V | 1622 | §102§112 | Non-Final OA | — | Pending | Aug 16, 2023 |
| 18234342 | SYSTEMS AND METHODS FOR CELL MANUFACTURING | Cellino Biotech, Inc. | NOBLE, MARCIA STEPHENS | 1632 | §102§103§112Other | Non-Final OA | — | Pending | Aug 15, 2023 |
| 18276802 | CXCR4-LIGANDS FOR DIAGNOSTIC AND THERAPEUTIC USE AND PRECURSORS THEREOF | Technische Universität München | RONEY, CELESTE A | 1612 | §103§112DP | Non-Final OA | — | Pending | Aug 10, 2023 |
| 18230480 | COMPOSITIONS AND METHODS FOR TREATING BRAIN INJURY | The Regents of the University of California | WEIDNER, ADAM M | 1675 | §103Other | Final Rejection | 10d overdue | Pending | Aug 04, 2023 |
| 18274823 | METHODS OF TREATING CANCERS USING STING AGONISTS | DANA-FARBER CANCER INSTITUTE, INC. | CRAIGO, BAHAR ALAWI | 1699 | §103 | Final Rejection | 12d | Pending | Jul 28, 2023 |
| 18226621 | THERAPEUTIC USES OF UROLITHIN DERIVATIVES | Vandria SA | WARD, PAUL V | 1622 | §102 | Non-Final OA | — | Pending | Jul 26, 2023 |
| 18226590 | UROLITHIN DERIVATIVES AND THERAPEUTIC USES | Vandria SA | KLINKEL, KORTNEY L | 1627 | §102§103 | Non-Final OA | — | Pending | Jul 26, 2023 |
| 18225961 | CONTINUOUS REACTOR AND ADDITIVE MANUFACTURING OF METALS WITH NANOSTRUCTURED INCLUSIONS | Northeastern University | ALDAZ CERVANTES, MAYELA RENATA | 1733 | §102§103§112 | Final Rejection | 5d overdue | Pending | Jul 25, 2023 |
| 18273466 | T CELL-DIRECTED ANTI-CANCER VACCINES AGAINST COMMENSAL VIRUSES FOR TREATING MUCOSAL CARCINOMAS | The General Hospital Corporation | JADHAO, SAMADHAN JAISING | 1672 | §102§103§112DP | Non-Final OA | — | Pending | Jul 20, 2023 |
| 17926847 | ANTIVIRAL POLYMERS | The University of Manchester | PIPIC, ALMA | 1617 | §103 | Final Rejection | 25d overdue | Pending | Jul 19, 2023 |
| 18223434 | VECTORS, GENETICALLY MODIFIED CELLS, AND GENETICALLY MODIFIED NON-HUMAN ANIMALS COMPRISING THE SAME | Regeneron Pharmaceuticals, Inc. | CONNORS, ALEXANDRA F | 1634 | §103§112DP | Non-Final OA | — | Pending | Jul 18, 2023 |
| 18272024 | LIPID NANOPARTICLES FOR TARGETED DELIVERY OF MRNA | The Brigham And Women'S Hospital, Inc. | PURDY, KYLE A | 1637 | §103§112DP | Non-Final OA | — | Pending | Jul 12, 2023 |
| 18271918 | QUANTUM COMPUTING SYSTEM AND METHOD | Odyssey Therapeutics UK Limited | GOODCHILD, WILLIAM J | 2433 | §102§103 | Non-Final OA | 6d | Pending | Jul 12, 2023 |
| 18221140 | MITOCHONDRIA-TARGETING PEPTIDES | Stealth BioTherapeutics Inc. | OTTON, ALICIA L | 1699 | §103§112 | Non-Final OA | 55d | Pending | Jul 12, 2023 |
| 18271913 | PHARMACEUTICAL FORMULATION | Redx Pharma PLC | CHANG, KYUNG SOOK | 1613 | §103 | Final Rejection | — | Pending | Jul 12, 2023 |
| 18350526 | COMPOSITIONS AND METHODS FOR REDUCING METHANE EMISSIONS IN RUMINANT POPULATIONS | Arkea Bio Corp. | JOHANSEN, PETER N. | 1644 | §112 | Final Rejection | — | Pending | Jul 11, 2023 |
| 18271503 | PRODUCTS AND METHODS FOR PROMOTING MYOGENESIS | ECOLE POLYTECHNIQUE FÉDÉRALE DE LAUSANNE | PAULUS, ERIN VIRGINIA | 1631 | §103§112 | Final Rejection | 4d overdue | Pending | Jul 10, 2023 |
| 18269869 | HEPATOCELLULAR CARCINOMA TREATMENTS, PROPHYLACTIC THERAPIES, AND COMPOSITIONS FOR USE THEREWITH | Repair Biotechnologies, Inc. | IANNUZO, NATALIE NMN | 1653 | §102§103 | Final Rejection | 50d overdue | Pending | Jun 27, 2023 |
| 18269168 | COMPOSITIONS AND METHODS RELATED TO BICYCLO[2.2.1] HEPTANAMINE-CONTAINING COMPOUNDS | The Brigham And Women'S Hospital, Inc. | OH, TAYLOR V | 1625 | §102§103 | Final Rejection | — | Pending | Jun 22, 2023 |
| 18268688 | DOSING REGIMENS FOR ORAL ALK2 KINASE INHIBITORS | Biocryst Pharmaceuticals, Inc. | HERNANDEZ, JACKSON J | 1627 | §103Other | Final Rejection | 56d | Pending | Jun 21, 2023 |
| 18257962 | COCRYSTAL OF A CDK INHIBITOR | Aurigene Discovery Technologies Limited | LEE, CHIHYI NMN | 1628 | §103§112DP | Non-Final OA | — | Pending | Jun 16, 2023 |
| 18210452 | METHODS FOR PREPARING DNA REFERENCE MATERIALS AND CONTROLS | Seracare Life Sciences, Inc. | JOHANNSEN, DIANA B | 1682 | §101§102§103§112DP | Non-Final OA | — | Pending | Jun 15, 2023 |
| 18256277 | COMPOSITIONS AND METHODS FOR MUCOSAL DRUG DELIVERY | The Schepens Eye Research Institute, Inc. | HELM, CARALYNNE E | 1615 | §103§112 | Final Rejection | — | Pending | Jun 07, 2023 |
| 18206368 | LETTUCE VARIETIES 'EZFLOR', 'BAUER', AND 'ADICAMP' | Enza Zaden Beheer B.V. | FAN, WEIHUA | 1663 | §112 | Final Rejection | 23d overdue | Pending | Jun 06, 2023 |
| 18265561 | LIPIDOID COMPOSITIONS AND METHODS OF USE THEREOF | Trustees Of Tufts College | KAMM, JUDITH MARIE | 1637 | §103§112DP | Non-Final OA | — | Pending | Jun 06, 2023 |
| 18265368 | USE OF SYNTHETIC COPOLYPEPTIDE HYDROGELS AS DERMAL FILLERS | The Regents of the University of California | LEE, JIA-HAI | 1658 | §103§112DP | Non-Final OA | — | Pending | Jun 05, 2023 |
| 18265380 | COMPOSITIONS AND METHODS FOR TREATING OCULAR DISEASES | Annexon, Inc. | ABBAS, SYED JARAR | 1674 | §102§103§112 | Non-Final OA | 44d overdue | Pending | Jun 05, 2023 |
| 18205096 | LIPID-LIKE NANOCOMPLEXES AND USES THEREOF | Trustees Of Tufts College | ANTHOPOLOS, PETER | 1611 | §103Other | Non-Final OA | — | Pending | Jun 02, 2023 |
| 18328200 | METHODS, SYSTEMS, AND DEVICES FOR SAMPLE INTERFACE | 10X Genomics, Inc. | LYLE, SOPHIA YUAN | 1796 | §103§112 | Final Rejection | 23d | Pending | Jun 02, 2023 |
| 18328295 | ASSEMBLY FOR FORMING A SEALED CHAMBER | 10X Genomics, Inc. | RAMIREZ, ALEX | 1798 | §103 | Final Rejection | — | Pending | Jun 02, 2023 |
| 18205305 | ENHANCING AUTOPHAGY OR INCREASING LONGEVITY BY ADMINISTRATION OF UROLITHINS | Amazentis SA | VALENROD, YEVGENY | 1628 | §103 | Non-Final OA | — | Pending | Jun 02, 2023 |
| 18202182 | METHODS AND COMPOSITION FOR TREATING METABOLIC SYNDROME | Zbiotics Company | PRAKASH, SUBBALAKSHMI | 1793 | §103 | Non-Final OA | 28d | Pending | May 25, 2023 |
| 18200875 | METAL CATIONS AS INORGANIC STRUCTURE DIRECTING AGENTS DURING THE SYNTHESIS OF PHILLIPSITE AND TOBERMORITE | The Regents of the University of California | FIGUEROA, JOHN J | 1763 | §102 | Non-Final OA | — | Pending | May 23, 2023 |
| 18254120 | METHODS AND SYSTEMS FOR TREATMENT OF INTERVERTEBRAL DISC BY INTRADISCAL MICRO-NEEDLE INSERTION | Discgenics, Inc. | BOSWORTH, KAMI A | 3783 | §102§103§112 | Non-Final OA | 28d | Pending | May 23, 2023 |
| 18037697 | METHODS OF TREATING DISEASES AND DISORDERS | Curis, Inc. | HUTTER, GILLIAN A | 1625 | §103DP | Final Rejection | — | Pending | May 18, 2023 |
| 18316464 | 3D Electrode Design for a High Specific-capacity Al-graphite Dual-ion Battery | Massachusetts Institute Of Technology | KYLE, MADISON LEIGH | 1722 | §103§112 | Final Rejection | 22d | Pending | May 12, 2023 |
| 18035373 | BINDING PROTEINS RECOGNIZING HA-1 ANTIGEN AND USES THEREOF | Tscan Therapeutics, Inc. | LEE, YIE CHIA | 1642 | §101§102§103§112 | Non-Final OA | — | Pending | May 04, 2023 |
| 18014623 | HETEROCYCLIC IMMUNOMODULATOR | BEIJING INNOCARE PHARMA TECH CO., LTD. | KUCKLA, ANNA GRACE | 1626 | §103 | Final Rejection | — | Pending | Apr 27, 2023 |
| 18033492 | ENHANCED HYT-INDUCED PROTEIN DEGRADATION USING LIPID NANOPARTICLE DELIVERY | Trustees Of Tufts College | ARMATO JR, DENNIS IGNATIUS | 1651 | §103§112 | Non-Final OA | 41d | Pending | Apr 24, 2023 |
| 18303527 | PROGRAMMABLE GENE EDITING USING GUIDE RNA PAIR | Massachusetts Institute Of Technology | KONOPKA, CATHERINE ANNE | 1635 | §102§103Other | Non-Final OA | — | Pending | Apr 19, 2023 |
| 18032067 | SUBSTITUTED ACYL SULFONAMIDES FOR TREATING CANCER | BAYER AKTIENGESELLSCHAFT | HIRAKIS, SOPHIA P | 1623 | §103DP | Final Rejection | 30d overdue | Pending | Apr 14, 2023 |
| 18132073 | HYBRID PEPPER 'E20S.10382' | Enza Zaden Beheer B.V. | BUI, PHUONG T | 1663 | §112 | Final Rejection | 121d overdue | Pending | Apr 07, 2023 |
| 18127887 | IMAGE QUANTIFICATION SYSTEM FOR ESTIMATION OF VIRAL LOAD BASED ON DETECTION BY RAPID ANTIGEN TEST | Hai Kang Life Corporation Limited | DUNN, MCKENZIE A | 1678 | §103§112 | Final Rejection | 23d overdue | Pending | Mar 29, 2023 |
| 18191495 | SLIDE-LEVEL UNCERTAINTY QUANTIFICATION FOR DEEP LEARNING PREDICTIONS IN DIGITAL HISTOPATHOLOGY | The University of Chicago | AUGER, NOAH ANDREW | 2122 | §101§102§103§112 | Non-Final OA | — | Pending | Mar 28, 2023 |
| 18027796 | ANTIMICROBIAL AQUEOUS COATINGS AND SEALANTS | Bmg ( British Medical Group) Limited | MAEWALL, SNIGDHA | 1612 | §103 | Non-Final OA | — | Pending | Mar 22, 2023 |
| 18026746 | METHODS OF TREATING AN INDIVIDUAL THAT HAS FAILED AN ANTI-PD-1/ANTI-PD-L1 THERAPY | DANA-FARBER CANCER INSTITUTE, INC. | BENAVIDES, JENNIFER ANN | 1675 | §102§103§112Other | Final Rejection | 18d overdue | Pending | Mar 16, 2023 |
| 18115223 | METHOD OF CALCULATING DIAGNOSTIC SCORE FOR PROSTATE CANCER AND USE THEREOF | Urotech. Co., Ltd. | LIN, JERRY | 1671 | §101DP | Non-Final OA | — | Pending | Feb 28, 2023 |
| 18114092 | USES OF UROLITHINS | Amazentis SA | GANGLE, BRIAN J | 1645 | §102 | Final Rejection | 36d overdue | Pending | Feb 24, 2023 |
| 18168340 | VASCULAR PROSTHESES, DELIVERY SYSTEMS, AND METHODS TO TREAT AORTIC ANEURYSMS AND DISSECTIONS | VASCUTEK LIMITED | LOPEZ, LESLIE ANN | 3774 | §102§103§112 | Final Rejection | — | Pending | Feb 13, 2023 |
| 18020473 | POLYMER ELECTROLYTE COMPOSITES | Ecolectro, Inc. | KEELING, ALEXANDER W | 1795 | §103 | Final Rejection | — | Pending | Feb 09, 2023 |
| 18018148 | SUBSTITUTED PYRROLO-PYRIDINONE DERIVATIVES AND THERAPEUTIC USES THEREOF | DANA-FARBER CANCER INSTITUTE, INC. | TOWNSLEY, SARA ELIZABETH | 1629 | §103Other | Final Rejection | 29d | Pending | Jan 26, 2023 |
| 18018207 | ARYL SUBSTITUTED PYRROLO-PYRIDINONES AND THERAPEUTIC USES THEREOF | DANA-FARBER CANCER INSTITUTE, INC. | MARTIN, KEVIN STEPHEN | 1624 | §112 | Final Rejection | 31d overdue | Pending | Jan 26, 2023 |
| 18017666 | NITROGEN-CONTAINING FUSED RING DERIVATIVE INHIBITOR, PREPARATION METHOD THEREFOR AND USE THEREOF | Jiangsu Hansoh Pharmaceutical Group Co., Ltd. | TOWNSLEY, SARA ELIZABETH | 1629 | §103 | Final Rejection | 71d | Pending | Jan 23, 2023 |
| 18014580 | INTERLEUKIN 33 (IL-33) INHIBITION FOR TREATMENT OF CANCER, FIBROSIS AND INFLAMMATION | The General Hospital Corporation | HERNANDEZ, JACKSON J | 1627 | §102§103 | Non-Final OA | 91d overdue | Pending | Jan 05, 2023 |
| 18013808 | COMPOSITIONS AND METHODS FOR MODULATING HAIR GROWTH | Pelage Pharmaceuticals, Inc. | FETTEROLF, BRANDON J | 1626 | §103§112Other | Non-Final OA | 14d | Pending | Dec 29, 2022 |
| 18012815 | HYDROGELS | Commonwealth Scientific And Industrial Research Organisation | STEINKE, SEAN JAMES | 1619 | §103 | Final Rejection | 31d overdue | Pending | Dec 23, 2022 |
| 18011577 | COMPOSITIONS AND METHODS FOR IDENTIFYING EPITOPES | Tscan Therapeutics, Inc. | AMICK, THOMAS RUSSE | 1638 | §103 | Non-Final OA | — | Pending | Dec 20, 2022 |
| 18084739 | ANTIBODY DRUG CONJUGATES COMPRISING TOXINS WITH POLAR GROUPS AND USES THEREOF | Intocell, Inc. | STONEBRAKER, ALYSSA RAE | 1642 | §102§103§112DP | Non-Final OA | — | Pending | Dec 20, 2022 |
| 18011354 | PRODRUGS OF MITOCHONDRIA-TARGETING OLIGOPEPTIDES | Stealth BioTherapeutics Inc. | KATAKAM, SUDHAKAR | 1658 | §103 | Non-Final OA | 26d | Pending | Dec 19, 2022 |
| 18067214 | PROGRAMMABLE INSERTION APPROACHES VIA REVERSE TRANSCRIPTASE RECRUITMENT | Massachusetts Institute Of Technology | SHEN, WU CHENG WINSTON | 1682 | §102§103§112DP | Non-Final OA | — | Pending | Dec 16, 2022 |
| 18007822 | METHODS OF TREATING A CORONAVIRUS INFECTION | The General Hospital Corporation | JOHNSON, CHRISTOPHER LINDSAY | 1691 | §103 | Non-Final OA | 3d overdue | Pending | Dec 02, 2022 |
| 17927639 | AGENTS AND METHODS FOR TREATING TAUOPATHIES | The Regents of the University of California | HERNANDEZ, JACKSON J | 1627 | §112 | Final Rejection | — | Pending | Nov 23, 2022 |
| 17927112 | NUCLEIC ACID ARTIFICIAL MINI-PROTEOME LIBRARIES | The Broad Institute, Inc. | LAFAVE, ELIZABETH ROSE | 1684 | §103§112 | Non-Final OA | — | Pending | Nov 22, 2022 |
| 17984639 | BINDING PROTEINS RECOGNIZING HPV16 E7 ANTIGEN AND USES THEREOF | Tscan Therapeutics, Inc. | DRISCOLL, MAUREEN VARINA | 1644 | §112DP | Non-Final OA | — | Pending | Nov 10, 2022 |
| 17923296 | COMPOSITIONS COMPRISING ENZYMES AND PROBIOTICS, AND METHODS FOR PREVENTING OR TREATING MACULAR DEGENERATION | Genofocus, Inc. | PAGUIO FRISING, MICHELLE F | 1651 | §103Other | Final Rejection | 34d | Pending | Nov 04, 2022 |
| 17977399 | CONSTRAINABLE STENT GRAFT, DELIVERY SYSTEM AND METHODS OF USE | Bolton Medical, Inc. | PRONE, CHRISTOPHER D | 3774 | §112 | Final Rejection | — | Pending | Oct 31, 2022 |
| 17972772 | CROMOLYN COMPOSITIONS AND METHODS THEREOF | The General Hospital Corporation | SASAN, ARADHANA | 1615 | §103 | Non-Final OA | — | Pending | Oct 25, 2022 |
| 17920588 | AFMT ANALOGS AND THEIR USE IN METHODS OF TREATING PARKINSON'S DISEASE | President and Fellows of Harvard College | WILSON, JERICA KATLYNN | 1621 | §102 | Non-Final OA | — | Pending | Oct 21, 2022 |
| 18048238 | DISCOVERY AND ENGINEERING OF INTEGRASES FOR HIGH-EFFICIENCY GENE INTEGRATION | Massachusetts Institute Of Technology | KONOPKA, CATHERINE ANNE | 1635 | §101§102§103§112DP | Non-Final OA | — | Pending | Oct 20, 2022 |
| 18047685 | GENOMIC EDITING WITH SITE-SPECIFIC RETROTRANSPOSONS | Massachusetts Institute Of Technology | ALLEN, SARAH ELIZABETH | 1637 | §103§112Other | Non-Final OA | — | Pending | Oct 19, 2022 |
| 17917233 | MANUFACTURING OF SYNTHETIC EXOSOMES FOR CNS AND NON-CNS DELIVERY OF THERAPEUTICS | The Regents of the University of California | RONEY, CELESTE A | 1612 | §103 | Final Rejection | 24d overdue | Pending | Oct 05, 2022 |
| 17938186 | TEST DEVICE | Spd Swiss Precision Diagnostics GmbH | CHIU, MAY LEUNG | 1758 | §102§103 | Non-Final OA | — | Pending | Oct 05, 2022 |
| 17953221 | SMALL MOLECULE INHIBITORS OF ONCOGENIC CHD1L WITH PRECLINICAL ACTIVITY AGAINST COLORECTAL CANCER | The Regents of the University of Colorado | AGUIRRE, AMANDA L | 1626 | §102 | Final Rejection | — | Pending | Sep 26, 2022 |
| 17947312 | METHODS FOR OBTAINING COMPOUNDS FROM A PLANT OR FUNGUS MATERIAL, RESPECTIVE COMPOSITIONS, AND USES THEREOF | Real Isolates, LLC | CHANDRAKUMAR, NIZAL S | 1625 | §103 | Final Rejection | 1d overdue | Pending | Sep 19, 2022 |
| 17903586 | COMPOSITIONS AND METHODS FOR STABILIZING BIOMOLECULES | Massachusetts Institute Of Technology | KIM, DANIELLE A | 1613 | §103 | Non-Final OA | 40d | Pending | Sep 06, 2022 |
| 17802824 | FUNCTIONAL HUMAN CORNEAL ENDOTHELIAL CELLS AND APPLICATION THEREOF | Kyoto Prefectural Public University Corporation | TINSLEY, BRENDAN THOMAS | 1634 | §112 | Final Rejection | — | Pending | Aug 26, 2022 |
| 17797610 | REAL-TIME DNN EXECUTION FRAMEWORK ON MOBILE DEVICES WITH BLOCK-BASED COLUMN-ROW PRUNING | College Of William & Mary | WERNER, MARSHALL L | 2125 | §101 | Non-Final OA | — | Pending | Aug 04, 2022 |
| 17796830 | METHODS AND COMPOSITIONS FOR IDENTIFYING CASTRATION RESISTANT NEUROENDOCRINE PROSTATE CANCER | Universita’ Degli Studi Di Trento | BUCHANAN, BAILEY CHEYENNE | 1682 | §101§103 | Non-Final OA | — | Pending | Aug 01, 2022 |
| 17877195 | COMBINATION THERAPY WITH NEOANTIGEN VACCINE | DANA-FARBER CANCER INSTITUTE, INC. | GODDARD, LAURA B | 1642 | §103§112 | Final Rejection | 19d overdue | Pending | Jul 29, 2022 |
| 17815844 | SYSTEMS FOR MEASURING PATIENT PHYSIOLOGIC PARAMETERS | UCHU Biosensors, Inc. | DOUGHERTY, SEAN PATRICK | 3791 | §112 | Non-Final OA | — | Pending | Jul 28, 2022 |
| 17868151 | SUPPORT RING FOR VASCULAR AORTIC REPAIR AND METHODS OF USE | Bolton Medical, Inc. | WOZNICKI, JACQUELINE | 3774 | §103 | Non-Final OA | 2d overdue | Pending | Jul 19, 2022 |
| 17791770 | STIMULATION OF HAIR GROWTH | The General Hospital Corporation | JOHNSON, CHRISTOPHER LINDSAY | 1691 | §103 | Non-Final OA | — | Pending | Jul 08, 2022 |
| 17787007 | ALUMINOSILICATE GLASS | Macquarie University | FORSYTH, PAUL ALAN | 1731 | §102§103 | Non-Final OA | — | Pending | Jun 24, 2022 |
| 17789019 | TARGETING THE INTRINSIC APOPTOTIC MACHINERY IN GLIOBLASTOMA | The Regents of the University of California | VALLE, ERNESTO | 1623 | §103 | Final Rejection | — | Pending | Jun 24, 2022 |
| 17807405 | Compositions, Methods and Systems for the Delivery of Gene Editing Material to Cells | Massachusetts Institute Of Technology | GROOMS, TIFFANY NICOLE | 1637 | §102§103 | Final Rejection | — | Pending | Jun 17, 2022 |
| 17838891 | SYNTHETIC LIPID-LIKE MATERIALS FOR BRAIN DELIVERY | Trustees Of Tufts College | DAVIS, BRIAN J | 1614 | §102 | Non-Final OA | 24d overdue | Pending | Jun 13, 2022 |
| 17781467 | COMPOSITIONS AND METHODS RELATED TO MOLECULAR CONJUGATION | Intocell, Inc. | CHANDRAKUMAR, NIZAL S | 1625 | §103Other | Final Rejection | 54d | Pending | Jun 01, 2022 |
| 17770463 | PATIENT-MATCHED ORGANOID SYSTEMS FOR STUDYING CANCER | Massachusetts Institute Of Technology | THUESON, HANNA MARIE | 1638 | §103 | Non-Final OA | — | Pending | Apr 20, 2022 |
| 17769180 | COMPOSITIONS AND METHODS FOR TREATING BLOOD DISORDERS | Annexon, Inc. | TAYLOR, LIA ELAN | 1641 | §103§112Other | Non-Final OA | — | Pending | Apr 14, 2022 |
| 17761946 | USE OF DKK-1 INHIBITORS FOR TREATING CANCER | Leap Therapeutics, Inc. | LU, CHENG | 1642 | §103DP | Final Rejection | 11d overdue | Pending | Mar 18, 2022 |
| 17642322 | SUPERCRITICAL DRYING OF CHROMATOGRAPHIC MEDIA | Merck Millipore Ltd. | LACLAIR, LOGAN EDWARD | 1736 | §103 | Final Rejection | 15d | Pending | Mar 11, 2022 |
| 17633254 | HYBRID AMIDE DERIVATIVES OF AMPHOTERICIN B | The Board Of Trustees Of The University Of Illinois | GALSTER, SAMUEL LEONARD | 1693 | §103DP | Final Rejection | 61d | Pending | Feb 07, 2022 |
| 17631169 | COMPOSITE MATERIALS | Anaphite Limited | MCKINNON, LASHAWNDA T | 1789 | §102§103 | Final Rejection | 34d | Pending | Jan 28, 2022 |
| 17572448 | CARBONATION SYSTEM FOR CURING OF CONCRETE PRODUCTS AT AMBIENT PRESSURE | Susteon Inc. | CHAU, LISA N | 1785 | §112 | Non-Final OA | 46d overdue | Pending | Jan 10, 2022 |
| 16964965 | ANTIBODY-DRUG CONJUGATES THAT TARGET DLK1 AND USES THEREOF | Y-Biologics, Inc. | PUTTLITZ, KARL J | 1646 | §103§112Other | Non-Final OA | 219d overdue | Pending | Nov 30, 2021 |
| 17603707 | THERAPEUTIC COMBINATIONS, LIQUID PHARMACEUTICAL COMPOSITIONS, KITS FOR THEIR PREPARATION, AND METHODS OF THEIR USE | Prevep, Inc. | DONOGHUE, BRITTNEY ERIN | 1675 | §112 | Non-Final OA | 85d overdue | Pending | Oct 14, 2021 |
| 17602076 | Enhancement of Melanocyte Migration Using ROCK Inhibitors | The General Hospital Corporation | MCKILLOP, JOHN CHARLES | 1637 | §103§112 | Final Rejection | 2d overdue | Pending | Oct 07, 2021 |
| 17598761 | MIXTURES OF SYNTHETIC COPOLYPEPTIDE HYDROGELS | The Regents of the University of California | BEANE, RANDALL L | 1654 | §103§112 | Non-Final OA | 16d overdue | Pending | Sep 27, 2021 |
| 17368346 | IL-12 COMPOSITIONS AND METHODS OF USE IN HEMATOPOIETIC RECOVERY | Karyopharm Therapeutics Inc. | GEORGE, DENNIS CHERIAN | 1644 | §112 | Non-Final OA | — | Pending | Jul 06, 2021 |
| 17311180 | HETEROCYCLYL POLYMETHINE IR CHROMOPHORES | The Regents of the University of California | CRAIG, KAILA ANGELIQUE | 1618 | §103 | Final Rejection | — | Pending | Jun 04, 2021 |
| 17284363 | COMBINATION OF AN UROLITHIN WITH AN IMMUNOTHERAPY TREATMENT | Amazentis SA | MOU, LIYUAN | 1628 | §103§112DPOther | Non-Final OA | — | Pending | Apr 09, 2021 |
| 17176464 | COMPUTER-IMPLEMENTED METHODS AND SYSTEMS FOR ACHIEVING REAL-TIME DNN EXECUTION ON MOBILE DEVICES WITH PATTERN-BASED WEIGHT PRUNING | College Of William & Mary | PRESSLY, KURT NICHOLAS | 2125 | §101 | Final Rejection | 3d overdue | Pending | Feb 16, 2021 |
| 17265934 | MODULATING PTPN2 TO INCREASE IMMUNE RESPONSES AND PERTURBING GENE EXPRESSION IN HEMATOPOIETIC STEM CELL LINEAGES | President and Fellows of Harvard College | CUNNINGCHEN, KATHLEEN MARY | 1646 | §101§103§112 | Non-Final OA | 12d | Pending | Feb 04, 2021 |
| 17255963 | NEW MOLECULAR TWEEZERS AGAINST NEUROLOGICAL DISORDERS AND VIRAL INFECTIONS | UNIVERSITAET ULM | RODRIGUEZ, RAYNA B | 1628 | §103 | Final Rejection | 29d overdue | Pending | Dec 23, 2020 |
| 17057432 | METHODS TO IDENTIFY STRUCTURAL VARIATIONS THAT CAUSE DISEASES AND THE REGIONS TO REPAIR WITH GENE EDITING | Williwaw Biosciences LLC | PULLIAM, JOSEPH CONSTANTINE | 1687 | §101§103§112 | Non-Final OA | 30d | Pending | Nov 20, 2020 |
| 17057060 | CHIMERIC ANTIGEN RECEPTORS WITH MODIFIED LINKER DOMAINS AND USES THEREOF | BIOSCEPTRE (AUST) PTY LTD | MIDDLETON, DANAYA L | 1674 | §112 | Final Rejection | 13d | Pending | Nov 19, 2020 |
| 17089448 | Diagnostic Method | Amazentis SA | FRITCHMAN, REBECCA M | 1758 | §103§112 | Non-Final OA | 49d overdue | Pending | Nov 04, 2020 |
| 16980679 | METHODS FOR TREATING OCULAR DISEASES | Novartis AG | FONTAINHAS, AURORA M | 1675 | §103Other | Non-Final OA | — | Pending | Sep 14, 2020 |
| 16640942 | METHODS FOR MODULATING THE INTERACTION BETWEEN EWS-FLI1 AND BAF COMPLEXES | The General Hospital Corporation | DENT, ALANA HARRIS | 1643 | §103§112 | Final Rejection | 87d overdue | Pending | Feb 21, 2020 |
| 16779005 | EXPANDABLE LUMINAL STENTS AND METHODS OF USE | Bolton Medical, Inc. | WOZNICKI, JACQUELINE | 3774 | §103§112 | Final Rejection | — | Pending | Jan 31, 2020 |
| 16490419 | DEVICES, METHODS, AND COMPOSITIONS USEFUL IN CRYO-PRESERVATION, -STORAGE, -TRANSPORT, AND APPLICATION OF THERAPEUTIC MAMMALIAN CELLS | Discgenics, Inc. | ABEL, LENORA A | 1799 | §103 | Non-Final OA | 15d overdue | Pending | Aug 30, 2019 |
| 16423344 | Portable Drug Mixing and Delivery Device and Associated Methods | Windgap Medical, Inc. | SCHMIDT, EMILY LOUISE | 3783 | §103 | Non-Final OA | — | Pending | May 28, 2019 |
| 16381791 | COMPOSITIONS AND METHODS OF IDENTIFYING TUMOR SPECIFIC NEOANTIGENS | DANA-FARBER CANCER INSTITUTE, INC. | HALVORSON, MARK | 1646 | §103 | Final Rejection | 93d overdue | Pending | Apr 11, 2019 |
| 16333855 | SCN9A ANTISENSE OLIGONUCLEOTIDES | Olipass Corporation | SHIN, DANA H | 1635 | §112DP | Non-Final OA | — | Pending | Mar 15, 2019 |
| 16094786 | IMPROVED HLA EPITOPE PREDICTION | The General Hospital Corporation | HALVORSON, MARK | 1646 | §103§112 | Final Rejection | 4d overdue | Pending | Oct 18, 2018 |
| 16078002 | HUMAN FUNCTIONAL CORNEAL ENDOTHELIAL CELL AND APPLICATION THEREOF | Kyoto Prefectural Public University Corporation | SCHUBERG, LAURA J | 1631 | §101§103DP | Non-Final OA | — | Pending | Aug 14, 2018 |
IP Author helps law firms respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial